Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an ...

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction ...

Please provide your email address to receive an email when new articles are posted on . The combination of anastrozole and fulvestrant extended median survival of women with hormone-receptor–positive ...

Please provide your email address to receive an email when new articles are posted on . Third-generation aromatase inhibitors, such as anastrozole and letrozole, are used as adjuvant therapy for ...

Dec. 9, 2004 (San Antonio) — Switching postmenopausal women to the aromatase inhibitor anastrozole after two years of adjuvant endocrine therapy with tamoxifen reduced the risk of breast cancer ...

Adjuvant therapy may include radiation therapy and some combination of chemotherapy, hormone therapy, and/or targeted therapy. Tamoxifen has been approved by the FDA for adjuvant hormone treatment of ...

4th European Breast Cancer Conference - Hamburg, Germany. March 17 2004: New data presented today 1,2, indicate that preoperative (neoadjuvant) treatment with ARIMIDEX TM (anastrozole) results in ...

Five years of tamoxifen has long been the standard adjuvant therapy for women with hormone-sensitive early-stage breast cancer; however, tamoxifen is associated with a number of adverse effects, and ...

Men with hypogonadism who receive anastrozole along with testosterone pellets (TP) maintain therapeutic levels of testosterone (T) longer than those treated with testosterone pellets alone, ...

The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women. While this is a major advance in prevention research, its impact on ...

SAN ANTONIO — Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may ...